Risk factors

Immix Biopharma faces substantial capital requirements, relying heavily on existing cash of $17.7 million and external grants. The company carries zero product revenues and depends entirely on unproven clinical candidates. Intellectual property defense and regulatory compliance dictate operational viability.

Trust certificate distributions rely entirely on the performance and unsecured obligations of the underlying securities portfolio. Certificateholders face risks of reduced pass-through rates and losses upon removal events or insufficient trust assets. Potential conflicts of interest exist with BofA Securities, Inc. as the entity that acquired the underlying portfolio.

Kiora Pharmaceuticals faces intense clinical, regulatory, and financial risks centered on its lead product candidates KIO-104 and KIO-301. The company has a history of substantial operating losses and requires additional capital to fund operations into 2027. Reliance on third-party collaborators like TOI and third-party manufacturers creates significant operational vulnerabilities.

Landmark Bancorp faces high exposure to Kansas real estate lending, particularly residential mortgages and commercial real estate.

The risks focus on completing the business combination by October 9, 2026 and preserving shareholder value.

Heavy reliance on a single major customer representing 90% of 2024 revenue creates extreme concentration risk. Operations depend heavily on U.S. government space contracts and federal funding continuity. Significant financial obligations under the Tax Receivable Agreement could require substantial cash payments to TRA holders.

Microbot operates as an early-stage medical device company facing continuous operating losses and dependence on the LIBERTY system. Operations and key personnel are heavily concentrated in Israel, creating regional geopolitical and military vulnerabilities. Intellectual property protection, regulatory approvals from the FDA and foreign bodies, and third-party manufacturing partnerships are critical to future commercialization.

Wellgistics Health depends heavily on third-party reimbursement, PBM relationships, and pharmaceutical distribution agreements like AmerisourceBergen. Integration risks from acquiring Wellgistics LLC and Wood Sage could hinder expected benefits. Goodwill and intangible assets represent 64 percent of total assets.

Accumulated deficit reached $180.7 million with a going concern warning and only $18 million in cash remaining.

Failure to complete the initial business combination by September 9, 2026 could trigger an extension and shareholder redemptions.

Trust certificate yields depend on call warrant exercise timing and prevailing interest rates. Certificate payouts depend entirely on underlying securities, guarantees, and swap agreements. The trustee does not actively manage or dispose of underlying securities.

Heavy geographic concentration in the Hudson Valley region exposes the bank to local economic and real estate downturns. Indirect automobile loans represent 30.3% of the total loan portfolio, creating substantial credit risk. Commercial real estate and business loans comprise 58.9% of the loan portfolio. Loss of Emerging Growth Company status increases regulatory burdens and costs. Balance sheet restructuring reduced accumulated other comprehensive loss on securities from $26.1 million to $10.5 million.